Abstract
During JADPRO Live Virtual 2021, Christine Cambareri, PharmD, BCPS, BCOP, CSP, briefed advanced practitioners on drugs and biologics that were approved for the treatment of solid tumors from late 2020 to late 2021, including their adverse event profiles. The trend of more oral dosage forms and the significant number of checkpoint inhibitors approved points towards changing treatment paradigms in the field.
